Led by pioneers in synthetic biology and computation, Senti is pioneering new technology platforms to design synthetic gene circuits for adaptive cell and gene therapies.
  • 2016 - Founded
  • 2018 - Partnered, Series A
  • 2022 - IPO; NASDAQ: SNTI

Partners

Great companies are being built by amazing teams.